- Home
- BMBL vs GLSI Comparison
BMBL vs GLSI Comparison
Compare BMBL & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMBL | GLSI |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.6M | 372.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BMBL | GLSI |
|---|---|---|
| Price | $3.03 | $24.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $4.65 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 2.8M | 263.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,071,643,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $2.61 | $7.78 |
| 52 Week High | $8.63 | $34.10 |
Technical Indicators
Market Signals| Indicator | BMBL | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 46.83 |
| Support Level | $2.61 | $23.06 |
| Resistance Level | $3.37 | $28.43 |
| Average True Range (ATR) | 0.19 | 2.61 |
| MACD | -0.03 | -0.90 |
| Stochastic Oscillator | 36.97 | 13.75 |
Price Performance
Historical ComparisonAbout BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.